DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is ...

Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system ...

Existing gene-editing technologies have led to significant advances in both medicine and food production. However, momentum appears to be slowing, particularly in health applications, as early hype is ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in human cells. The coming together of ...

The National Institutes of Health will launch a research program to encourage the development of genome-editing treatments for various diseases. Under the Somatic Cell Genome Editing program, the NIH ...

Growing focus on gene-based therapies, advances in editing tools, and increasing research investments are accelerating the adoption of genome editing technologies across life sciences and agriculture.

Recent scientific advances have made genome editing technologies—a suite of biological tools for making precise additions, deletions, and alterations to the DNA and RNA of living cells– more rapid, ...